Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 9/20 | 0.41 |
| ▸ | HTR2A | P28223 | 6/20 | 0.40 |
| ▸ | HTR2B | P41595 | 6/20 | 0.40 |
| ▸ | HTR6 | P50406 | 2/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.36 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3085122 | 1.00 | HTR2C (0.41) | HTR2CHTR2AHTR2BHTR6CHRNB2 | |
| SCHEMBL6644276 | 0.82 | NOS3 (0.47) | PARP10PARP11KMT2AACHECA1 | |
| SCHEMBL3075858 | 0.74 | HTR2C (0.39) | HTR2CHTR2AHTR2BKMT2A | |
| SCHEMBL3075861 | 0.74 | HTR2C (0.39) | HTR2CHTR2AHTR2BKMT2A | |
| SCHEMBL3445529 | 0.69 | HTR2C (0.68) | HTR2CHTR2AHTR2BCHRNB2CHRNA4 | |
| SCHEMBL31521243 | 0.68 | SLC6A1 (0.32) | HTR2CHTR2A | |
| SCHEMBL1895364 | 0.68 | HTR2C (0.43) | HTR2CHTR2AHTR2BCHRNB2CHRNA4 | |
| SCHEMBL11834071 | 0.68 | HTR2C (0.42) | HTR2CHTR2AHTR2BHTR6CHRNB2 | |
| SCHEMBL29400162 | 0.68 | HTR2C (0.42) | HTR2CHTR2AHTR2BHTR6CHRNB2 | |
| SCHEMBL11840313 | 0.66 | HTR2C (0.40) | HTR2CHTR2AHTR2BHTR6CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070049613-A1 | Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-01 | — | — | US | claimed |
| US-7795436-B2 | Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-14 | — | — | US | disclosed |
| US-20070049613-A1 | Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049613-A1 | Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists | HTR2B, HTR2C, HTR1A | HTR2C 2/4885HTR2A 8/4885HTR2B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.